Navigation Links
Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia

rantee that a registrational submission will be made to the FDA based on the data described in this press release or if such registrational submission is made, that it would receive FDA approval. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol- Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2006 and in our Quarterly Reports on Form 10-Q. Bristol-Myers Squibb undertakes no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise.

    (1) Robb AS, Forbes RA, Marcus RN, Carson Jr. WH. Efficacy of aripiprazole

    in the treatment of adolescents with schizophrenia. Poster presentation

    NR742 at: annual meeting of the American Psychiatric Association, San

    Diego, California, Wednesday, May 23, 2007, 3:00 p.m. - 5:00 p.m. PST -

    Poster Session 7.


    (2) Findling RL, Nyilas M, Auby P, Mallikaarjun S, McQuade RD, Marcus RN,

    Carson Jr. WH. Tolerability of aripiprazole in the treatment of

    adolescents with schizophrenia. Poster presentation NR741 at: annual

    meeting of the American Psychiatric Association, San Diego, California,

    Wednesday, May 23, 2007, 3:00 p.m. - 5:00 p.m. PST - Poster Session 7.


    (3) IMS Auditrac NGPS: Abilify total monthly retail prescriptions: Data

    accessed 11/2006.

CONTACT: Debra Kaufmann of Otsuka America Pharmaceutical, Inc.,+1-240-683-3568, ; or Hideki Shirai of OtsukaPharmaceutical Co., Ltd., +81-3-3292-0021, ; or David M.Rosen, Communications, +1-609-252-5675, Pager, +1-866-308-4484,, or John Elicker, Investor Relations,+1-212-546-3775, , both of Bristol-Myers Squibb Company debra.kaufmann@otsuka.com




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
(Date:8/29/2014)... -- Pixcelldata, the innovative Irish developer of ... major new deal with Dutch based eX-Path, global providers ... Marius Nap . The announcement was ... Pathology which is taking placing between August 30th and ... where Pixcelldata will demonstrate its innovative solution. ...
(Date:8/28/2014)...  Rigrodsky & Long, P.A.: , Do you, ... LCI )? , Did you purchase your shares before ... 2014, inclusive? , Did you lose money in your ... to discuss your rights? Rigrodsky & ... Timothy J. MacFall , announces that a complaint has been filed ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
(Date:8/30/2014)... As the economy continues to recover ... style bathrooms and in-home fitness centers, the North ... in interest not only in designing and installing saunas ... benefits of sauna. Through working with manufacturers across ... Sauna Society provides a strong knowledge base of Finnish ...
(Date:8/30/2014)... 2014 UWDress.com, a distinguished wedding dress supplier, ... first range of fashionable outfits. Recently, the company has unveiled ... As an autumn special offer, all these brand new products ... , “We are excited to unveil the new and ... high quality products are available at low prices now. The ...
(Date:8/30/2014)... 2014 Recently, Skmen.com, a well-known clothing ... casual dresses . Before the middle of September, all ... discounted price, from 15 to 30 percent off. ... long casual outfits are carefully made and come with ... for the wearers. Skmen.com is popular for its fashionable, ...
(Date:8/30/2014)... Patients suffering from vitiligo can now discover a ... published by Daily Gossip. , Vitiligo is a ... no wonder that numerous sufferers search for an alternative ... one of the most appreciated such methods at the ... the spread of this disorder immediately, while completely curing ...
(Date:8/30/2014)... 30, 2014 The term nutraceuticals ... Pharameuticals. Nutraceuticals is a source of healthy-dietary supplements ... natural food sources. Nutraceutical ingredients have certain curative ... human body. Nutraceutical health products include factors such ... and more. Although nature is the most bountiful ...
Breaking Medicine News(10 mins):Health News:As Interest in Saunas Increases, the North American Sauna Society Increases Outreach to Provide Education on History, Design, and Culture 2Health News:UWDress.com’s Beautiful Collection Of “Flowy Bridesmaid Dresses” Released 2Health News:Huge Deals On 2014 Long Casual Dresses Unveiled By Skmen.com 2Health News:Natural Vitiligo Treatment Review Exposes Fast Method for Skin Repigmentation 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4
... SHENZHEN, China, Feb. 13 /PRNewswire-Asia/ -- Winner Medical Group Inc.,(OTC ... financial results for the first quarter ended December 31,2008. The ... with,the United States Securities and Exchange Commission. , , ... Total net sales revenue increased by 33.14% over the first ...
... the University of Brighton Medical School has chosen a Mecmesin MultiTest ... orthopaedic prosthesis for shoulder reconstruction. , ... Slinfold, West ... orthopaedic surgeon at the University of Brighton Medical School has chosen ...
... share most of their genes, including 70 percent of ... remarkable evolutionary conservation, researchers at the Salk Institute for ... model for an innovative study of gliomas, the most ... disease but we still know very little about the ...
... 44%, researchers say , , THURSDAY, Feb. 12 (HealthDay News) ... much as a 44 percent increased risk of developing ... has established a connection between smoking and increased risk ... the largest review to date showing a link between ...
... Feb. 12 Biotel Inc.,(OTC Bulletin Board: BTEL) announced ... net earnings of $289,000, or $0.10 per diluted share,on ... $206,000, or $0.07,per diluted share, on revenues of $2,859,000 ... months ended December 31, 2008, Biotel had net earnings ...
... The Pennsylvania Department of Health has reviewed and ... Hospital in Brownsville, Fayette County, which ceased operations ... have been relocated to other facilities. All hospital ... work, assisted with the patient transfer.Local ambulances and ...
Cached Medicine News:Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 2Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 3Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 4Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 5Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 6Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 7Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 8Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 9Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 10Health News:Force Tester Shoulders The Burden 2Health News:Fruit flies soar as lab model, drug screen for the deadliest of human brain cancers 2Health News:Fruit flies soar as lab model, drug screen for the deadliest of human brain cancers 3Health News:Secondhand Smoke Linked to Dementia 2Health News:Biotel Announces Profitable Second Quarter Ended December 31, 2008 2
... is based on SIREMOBIL Iso-C, the first ... the intra-operative 3D-Mode, the 3D-dataset is immediately ... orbital movement. This allows the surgeon to ... during the procedure. This 3D capability is ...
... Humphrey Field Analyzer II-i series is a ... the patient's visual field. ,By using SITA, ... is reduced by up to 70%. ,A ... ergonomic design to increase patient comfort while ...
... an innovative device designed to be a ... abdominal aortic aneurysms (AAA). It is constructed ... an outer self-expanding Nitinol support structure to ... The function of the endoprosthesis is to ...
... a cast from an arm or leg can ... cut or burned by the cast saw blade. ... remove any cast with confidence. This innovative, cut-resistant ... burns from the cast saw and can be ...
Medicine Products: